DMPA-SC resources and references
Mounting evidence and experience shows that integrating DMPA-SC across multiple delivery channels in a country’s family planning program can help expand contraceptive access and options.
By collaborating with ministries of health and partners, PATH has generated a rich repository of experience and evidence on the injectable contraceptive, subcutaneous DMPA (DMPA-SC, brand name Sayana® Press). The following resources can support countries, implementing partners, and donors interested in introducing or scaling up this new contraceptive option in their family planning programs.
- Key fact sheets about DMPA-SC
- A list of references about subcutaneous DMPA
- DMPA-SC webinars
- Advocacy and communications tools
- Feasibility and acceptability of Sayana Press
- DMPA-SC self-injection resources
- Evidence and Guidance: Hormonal contraception and HIV
*DMPA-SC: Subcutaneous depot medroxyprogesterone acetate.
Sayana Press is a registered trademark of Pfizer Inc. Uniject is a trademark of BD.